肝动脉灌注化疗(HAIC)对中晚期HCC治疗的临床研究

Clinical Study of Hepatic Artery Infusion Chemotherapy (HAIC) for the Treatment of Advanced HCC

摘要: 原发性肝细胞癌(hepato cellular carccinoma, HCC)是世界常见六大恶性肿瘤之一，早期诊断、早期治疗能使患者最大程度获益。由于其发病的隐匿性，大多数病人在有了一定的临床表现时才前往医院，初诊时已经是中晚期，失去了外科手术的机会。介入治疗针对中晚期HCC的血管介入治疗方式主要有经肝动脉化疗栓塞(transcatheter arterial chemoembolization, TACE)、肝动脉灌注化疗(hepatic arterial infusion chemotherapy, HAIC)等，TACE作为传统的治疗方式一直深受医师学者的认可，其治疗效果和安全性都是明确的，而HAIC目前尚未形成统一的诊疗标准及规范，本文就肝动脉灌注化疗对中晚期HCC治疗的临床研究进行阐述。

Abstract: Primary hepatocellular carcinoma (HCC) is one of the six common malignant tumors in the world. Early diagnosis and treatment can maximize the benefits for patients. Due to the insidious nature of its onset, most patients only go to the hospital when they have certain clinical manifestations, and the initial diagnosis is already in the middle and late stages, losing the opportunity for surgical surgery. Interventional therapy for advanced HCC mainly includes transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc. TACE has been widely recognized by physicians and scholars as a traditional treatment method, and its therapeutic effect and safety are clear. However, HAIC has not yet formed a unified diagnosis and treatment standard. This article elaborates on the clinical research of hepatic arterial infusion chemotherapy for the treatment of advanced HCC.